UCLA researchers unveiled a lipid nanoparticle gene‑editing platform capable of inserting a full‑length healthy gene into human airway cells, addressing a key delivery and payload size limitation for cystic fibrosis (CF) gene therapy. The study demonstrates precise delivery and expression in airway epithelium ex vivo and in relevant models. The approach aims to overcome vector‑capacity constraints that have hindered universal gene replacement strategies. If translated into the clinic, the technology could broaden gene therapy options for CF and other genetic lung diseases that require delivery of large coding sequences.